MetaCap

Vera Therapeutics Inc. Class A (VERA)

NASDAQ: VERAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

25.45-1.30 (-4.86%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

VERA stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$5.90
52-week range
25.08 – 56.05
Day range
25.16 – 27.15
Volume / Avg
1.37M / 1.95M
Beta
—

52-week range

$25.08$56.05

VERA stock today

On Nov 20, VERA ended the session at $25.45, shedding $1.30 (4.86%), versus the S&P 500's 3.70% decline. At this level, VERA sits near the bottom of its 52-week range of $25.08 to $56.05: 54.6% below the high, set on Dec 24, 2025 and 1.5% above the low. VERA is down 49.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 10.6%.

Vera Therapeutics has posted a net loss over the last twelve months (EPS of -$5.90), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Vera Therapeutics

Company profile

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Marshall W. Fordyce M.D.
Headquarters
Brisbane, CA
Employees
362
IPO year
2021
Website
veratx.com

Financial highlights

Full financials

Vera Therapeutics reported a net loss of $299.6 million, compared with a loss of $152.1 million a year earlier. Diluted earnings per share came in at -$4.66.

Vera Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-299.62M$-152.15M$-95.99M$-89.06M$-32.61M
EPS (diluted)$-4.66$-2.75$-2.25$-3.35$-2.43

Analyst forecast

Forecast

Consensus (14 analysts)

strong_buy

Avg. price target

$71.36+180.39%

  • Strong buy 1
  • Buy 11
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $29.00High $100.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-1.26 vs $-1.72
Surprise
+26.74%

VERA news

All VERA news

Vera Therapeutics peers

Health Care sector
VERA peer companies
CompanyPrice% ChgMarket capCompare
SEPNSepterna Inc.38.61-1.51%$1.84Bvs VERA
IMNMImmunome Inc.15.69-5.54%$1.85Bvs VERA
MRVIMaravai LifeSciences Holdings Inc. Class A6.98-2.92%$1.81Bvs VERA
BHVNBiohaven Ltd.12.39-9.23%$1.87Bvs VERA
ZYMEZymeworks Inc.26.14-2.68%$1.81Bvs VERA
TRVITrevi Therapeutics Inc.13.35-2.70%$1.90Bvs VERA
HRMYHarmony Biosciences Holdings Inc.32.59-1.18%$1.91Bvs VERA
ETONEton Pharmaceuticals Inc.60.85-0.83%$1.76Bvs VERA

Indexes, lists and sector

Vera Therapeutics stock FAQ

What is Vera Therapeutics's stock price today?

VERA last traded at $25.45 as of Nov 20, 4:00 PM EST, down 4.86% on the day. Prices are delayed at least 15 minutes.

Who is Vera Therapeutics's CEO?

Dr. Marshall W. Fordyce M.D. is the chief executive officer of Vera Therapeutics Inc. Class A, which has about 362 employees.

What is the VERA 52-week high?

The 52-week high for VERA is $56.05 and the 52-week low is $25.08. The stock is currently 54.6% below its high.

Compare VERA